CSL Ltd (CSLLY)
94.01
-1.28
(-1.34%)
USD |
OTCM |
May 17, 16:00
CSL Enterprise Value: 103.94B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 103.94B |
| May 16, 2024 | 105.17B |
| May 15, 2024 | 104.86B |
| May 14, 2024 | 102.84B |
| May 13, 2024 | 102.13B |
| May 10, 2024 | 102.38B |
| May 09, 2024 | 101.74B |
| May 08, 2024 | 101.82B |
| May 07, 2024 | 102.34B |
| May 06, 2024 | 101.73B |
| May 03, 2024 | 101.21B |
| May 02, 2024 | 101.08B |
| May 01, 2024 | 99.23B |
| April 30, 2024 | 99.67B |
| April 29, 2024 | 100.71B |
| April 26, 2024 | 99.67B |
| April 25, 2024 | 100.22B |
| April 24, 2024 | 100.16B |
| April 23, 2024 | 100.75B |
| April 22, 2024 | 99.26B |
| April 19, 2024 | 96.99B |
| April 18, 2024 | 97.08B |
| April 17, 2024 | 98.09B |
| April 16, 2024 | 97.96B |
| April 15, 2024 | 99.58B |
| Date | Value |
|---|---|
| April 12, 2024 | 101.52B |
| April 11, 2024 | 101.50B |
| April 10, 2024 | 101.99B |
| April 09, 2024 | 102.87B |
| April 08, 2024 | 103.04B |
| April 05, 2024 | 102.28B |
| April 04, 2024 | 102.54B |
| April 03, 2024 | 102.69B |
| April 02, 2024 | 103.09B |
| April 01, 2024 | 103.44B |
| March 28, 2024 | 104.21B |
| March 27, 2024 | 103.81B |
| March 26, 2024 | 102.29B |
| March 25, 2024 | 102.35B |
| March 22, 2024 | 101.49B |
| March 21, 2024 | 100.72B |
| March 20, 2024 | 101.98B |
| March 19, 2024 | 101.08B |
| March 18, 2024 | 101.44B |
| March 15, 2024 | 101.56B |
| March 14, 2024 | 102.27B |
| March 13, 2024 | 102.97B |
| March 12, 2024 | 102.99B |
| March 11, 2024 | 102.63B |
| March 08, 2024 | 104.13B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
67.51B
Minimum
May 29 2019
118.27B
Maximum
Feb 03 2023
96.07B
Average
96.93B
Median
Nov 02 2020
Enterprise Value Benchmarks
| Alterity Therapeutics Ltd | -- |
| Kazia Therapeutics Ltd | 5.257M |
| Immutep Ltd | -- |
| Opthea Ltd | 125.45M |
| Mesoblast Ltd | -- |
Enterprise Value Related Metrics
| Earnings Yield | 2.71% |
| Operating Earnings Yield | 2.77% |
| Normalized Earnings Yield | 2.707 |